Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Soleno Therapeutics Added to Russell 3000(R) Index

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has been added...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters' Option to Purchase Additional Shares

Soleno Therapeutics, Inc. (Nasdaq: SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing...

SLNO : 2.12 (+1.44%)
Translate Bio (TBIO) in Focus: Stock Moves 11.7% Higher

Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

TBIO : 17.54 (+0.80%)
SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock

Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Soleno Therapeutics, Inc. (Nasdaq: SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that...

SLNO : 2.12 (+1.44%)
Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session

Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

SLNO : 2.12 (+1.44%)
ATXI : 9.70 (-4.15%)
Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Soleno Therapeutics, Inc. (SLNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Study Did Not Meet Statistical Significance for Primary Endpoint, but Showed Significant Improvements in Prespecified Subgroup with Severe Hyperphagia

SLNO : 2.12 (+1.44%)
Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options

Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity

Paper Published in Peer-Reviewed Journal, Genes, as Part of Special Supplement on Genetics of Prader-Willi Syndrome (PWS)

SLNO : 2.12 (+1.44%)
Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D.,...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced...

SLNO : 2.12 (+1.44%)
Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates

Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.

UTHR : 118.60 (-0.37%)
JAZZ : 108.78 (-2.18%)
USNA : 81.28 (+2.15%)
SLNO : 2.12 (+1.44%)
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

CORT : 16.59 (-0.78%)
PCRX : 54.17 (-0.17%)
ACRX : 1.1300 (+6.60%)
SLNO : 2.12 (+1.44%)
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

Soleno Therapeutics, Inc. (SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock

Soleno Therapeutics, Inc. (SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Soleno Therapeutics, Inc. (SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends...

SLNO : 2.12 (+1.44%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.61 , SEDG -2.31 , THC -0.85 , TER -1.79 , LITE -1.27
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar